Fact Sheet for Healthcare Providers: Quick SARS-CoV-2 rRT-PCR Kit –Zymo Research Corporation
Source: U.S. Food and Drug Administration (FDA). Published: 5/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Quick SARS-CoV-2 rRT-PCR Kit, which received an Emergency Use Authorization from the Food and Drug Administration on May 7, 2020. The Quick SARS-CoV-2 rRT-PCR Kit is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 7, 2020 Category: International Medicine & Public Health Source Type: news

Fact Sheet for Healthcare Providers: Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay
Source: U.S. Food and Drug Administration (FDA). Published: 5/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay, which received an Emergency Use Authorization from the Food and Drug Administration on May 7, 2020. The Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay is authorized for use on respiratory specimens from individuals suspected of coronavirus disease 2019 (COVID-19) by their healthcare provider. (PDF) (Source: Disaster Lit: Resource Guide f...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 7, 2020 Category: International Medicine & Public Health Source Type: news

Fact Sheet for Healthcare Personnel: Duke Decontamination System for Decontaminating Compatible N95 Respirators
Source: U.S. Food and Drug Administration (FDA). Published: 5/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of decontaminated, compatible N95 respirators. These compatible N95 respirators have been decontaminated using the Duke Decontamination System with Hydrogen Peroxide Vapor, which received an Emergency Use Authorization from the Food and Drug Administration on May 7, 2020. (PDF) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 7, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19 and the Use of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers
Source: World Health Organization (WHO). Published: 5/7/2020. This brief summarizes the current evidence on the impact of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers on severe acute respiratory illness due to SARS CoV-2. It addresses concerns that ACE inhibitors and angiotensin receptor blockers (ARBs) increase susceptibility to coronavirus SARS CoV-2 (the viral agent that causes the disease COVID-19) and the likelihood of severe COVID-19 illness. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 7, 2020 Category: International Medicine & Public Health Source Type: news

FAQs on Shortages of Surgical Masks and Gowns During the COVID-19 Pandemic
Source: U.S. Food and Drug Administration (FDA). Published: 5/7/2020. This web page, updated on May 7, 2020, provides answers to frequently asked questions about shortages of surgical masks and gowns during the COVID-19 pandemic. Other topics include how manufacturers of personal protective equipment (PPE) who may be considering increasing availability of these products to the U.S. market can engage with the FDA; if expired masks and gowns can be used; and how to find the manufacturer-designated shelf life of a product. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 7, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19 Case Management in Humanitarian and Low-Income Settings: Dilemmas and Decisions
Source: Johns Hopkins University. Published: 5/6/2020. This one-hour webinar tackles the difficult but central issue of how to manage COVID-19 patients in humanitarian responses and low-income settings. It discusses decision-making on which services to offer and dilemmas to consider, and discusses a real-life scenario treating patients in Sudan. (Video or Multimedia) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19 Critical Infrastructure Sector Response Planning
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 5/6/2020. Functioning critical infrastructure is imperative during the response to the COVID-19 emergency for both public health and safety, as well as community well-being. This web page provides information about creating a COVID-19 Critical Infrastructure Response Plan, and CDC Interim Guidance for Critical Infrastructure Workers Exposed to COVID-19. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

Responding to the Needs of Youth Involved With the Justice System During the COVID-19 Pandemic
Source: American Academy of Pediatrics (AAP). Published: 5/6/2020. The COVID-19 pandemic presents unique challenges to the health and well-being of youth involved with the justice system. This web page provides recommendations for juvenile justice agencies. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19: Forewarned, But Not Forearmed
Source: Bipartisan Commission on Biodefense. Published: 5/6/2020. This two-hour, 18-minute virtual meeting of the Bipartisan Commission on Biodefense discusses having a better understanding of the ongoing response to novel coronavirus 2019 (COVID-19), national readiness to address possible large-scale spread of the disease in the United States and throughout the world, and implications for improving preparedness for the next biological threat. (Video or Multimedia) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19 Response
Source: U.S. House of Representatives, Committee on Appropriations. Published: 5/6/2020. In this two-hour, 43-minute Congressional hearing, witnesses discuss views of the path forward for responding to the COVID-19 pandemic, and based on 30 years of fighting epidemics -- including the Centers for Disease Control and Prevention ’s response to Ebola -- propose a new approach to bring stability and security to the efforts to keep Americans safer from epidemics. (Video or Multimedia) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

Operational Toolkit for Businesses Considering Reopening or Expanding Operations in COVID-19
Source: Center for Health Security [Johns Hopkins University, Bloomberg School of Public Health]. Published: 5/6/2020. This operational toolkit has been developed to help business owners who are considering reopening or expanding their operations to determine their establishments ’ risk of transmission of COVID-19 and how to reduce it. It contains three parts: an instruction manual; a business risk worksheet; and an assessment calculator. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

Fact Sheet for Healthcare Providers: SARS-COV-2 R-GENE ® - BIOMÉRIEUX
Source: U.S. Food and Drug Administration (FDA). Published: 5/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the SARS-COV-2 R-GENE ® test, which received an Emergency Use Authorization from the Food and Drug Administration on May 6, 2020. The SARS-COV-2 R-GENE® test is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

Fact Sheet for Healthcare Providers: Sherlock ™ CRISPR SARS-CoV-2 Kit - Sherlock BioSciences, Inc.
Source: U.S. Food and Drug Administration (FDA). Published: 5/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Sherlock ™ CRISPR SARS-CoV-2 kit, which received an Emergency Use Authorization from the Food and Drug Administration on May 6, 2020. The Sherlock™ CRISPR SARS-CoV-2 kit is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

Fact Sheet for Healthcare Providers: OPTI SARS-CoV-2 RT PCR Test - OPTI Medical Systems Inc.
Source: U.S. Food and Drug Administration (FDA). Published: 5/6/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the OPTI SARS-CoV-2 RT PCR Test, which received an Emergency Use Authorization from the Food and Drug Administration on May 6, 2020. The OPTI SARS-CoV-2 RT PCR Test is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news

Telling Our Stories in the Age of COVID-19
This study is intended to better understand the day-to-day impact of the novel coronavirus on the lives of the global public. Using regular journal entries along with several open- and close-ended questions specific to the impact of COVID-19, we aim to understand personal experiences of the global pandemic as it occurs in real time. We are specifically interested in situational changes, COVID-19 exposure and experience, COVID-19-related concerns, daily mood changes, and perceived impact, mental health impact, and use of social media. Study Population: As of May 6, 2020, participants represent 29 countries and 35 states wi...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 6, 2020 Category: International Medicine & Public Health Source Type: news